Latest News: Indian share markets will be open for trading on Sunday, February 01, as the Union Budget is being presented on that day * Key Highlights of Economic Survey 2025–26: GDP & GVA Growth Estimates for FY 2026: First advance estimates at 7.4% and 7.3% respectively * India’s Core Growth Projection: Around 7%, with real GDP growth for FY 2027 expected between 6.8% and 7.2% * Central Government Revenue: Rose to 11.6% of GDP in FY 2025 * Non-Performing Assets: Declined to a multi-decade low of 2.2% * PMJDY Accounts: Over 552 million bank accounts opened by March 2025; 366 million in rural and semi-urban areas * Investor Base: Surpassed 120 million by September 2025, with women comprising ~25% * Global Trade Share: India’s export share doubled from 1% in 2005 to 1.8% in 2024 * Services Export: Reached an all-time high of $387.6 billion in FY 2025, up 13.6% * Global Deposits: India became the largest recipient in FY 2025 with $135.4 billion * Foreign Exchange Reserves: Hit $701.4 billion on January 16, 2026—covering 11 months of imports and 94% of external debt * Inflation: Averaged 1.7% from April to December 2025 * Foodgrain Production: Reached 357.73 million metric tons in 2024–25, up 25.43 MMT from the previous year * PM-Kisan Scheme: Over ₹4.09 lakh crore disbursed to eligible farmers since inception * Rural Employment Alignment: “Viksit Bharat – Jee Ram Ji” initiative launched to replace MGNREGA in the vision for a developed India by 2047 * Manufacturing Growth: 7.72% in Q1 and 9.13% in Q2 of FY 2026 * PLI Scheme Impact: ₹2 lakh crore in actual investment across 14 sectors; production and sales exceeded ₹18.7 lakh crore; over 1.26 million jobs created by September 2025 * Semiconductor Mission: Domestic capacity boosted with ₹1.6 lakh crore invested across 10 projects * Railway High-Speed Corridor: Expanded from 550 km in FY 2014 to 5,364 km; 3,500 km added in FY 2026 * Civil Aviation: India became the third-largest domestic air travel market; airports increased from 74 in 2014 to 164 in 2025 * DISCOMs Turnaround: Recorded first-ever positive PAT of ₹20,701 crore in FY 2025 * Renewable Energy: India ranked third globally in total renewable and installed solar capacity * Satellite Docking: India became the fourth country to achieve autonomous satellite docking capability * School Enrollment Ratios: Primary – 90.9%, Upper Primary – 90.3%, Secondary – 78.7% * Higher Education Expansion: India now has 23 IITs, 21 IIMs, and 20 AIIMS; international IIT campuses established in Zanzibar and Abu Dhabi * Maternal & Infant Mortality: Declined since 1990, now below global average * E-Shram Portal: Over 310 million unorganised workers registered by January 2026; 54% are women * National Career Service Portal: Job vacancies exceeded 28 million in FY 2025 and crossed 23 million by September 2026

Combination of ‘Siddha’ drugs reduces Anemia in adolescent girls


A recent study published in the reputed Indian Journal of Traditional Knowledge by researchers conducting the PHI-Public Health Initiative claims the drug reduces anaemia among adolescent girls. The initiative was undertaken to mainstream the use of ‘Siddha’ drugs to combat anaemia.

The group of researchers from eminent Siddha institutions of the country, including the National Institute of Siddha, Ministry of Ayush; Xavier Research Foundation, and Velumailu Siddha Medical College & Hospital of Tamilnadu.

Read in Hindi: 'सिद्ध' दवाओं से ठीक हो रही है किशोरियों में एनीमिया बीमारी

The researchers found that ABMN, i.e. Aṉṉapēticentūram, Bāvaṉa kaṭukkāy, Mātuḷai maṇappāku and Nellikkāy lēkiyam, a combination of Siddha drug treatment can improve the level of Haemoglobin as well as PCV-Packed cell volume, MCV-Mean Corpuscular Hemoglobin and MCH-Mean Corpuscular Hemoglobin in the anaemic adolescent girls.

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme. Reportedly, before the start of the programme, researchers dewormed the participants with Cuṇṭaivaṟṟal cūraṇam, and then a 45-day treatment of ABMN was given to all participants under observation.

The study noted that the presence of clinical features like breathlessness, fatigue, giddiness, headache, anorexia, and pallor was evaluated by the investigators before and after completion of the programme, along with Hemoglobin evaluation and biochemical estimations.

Following the WHO guidelines, the cut-off point for anaemia was set as 11.9 mg/dl, haemoglobin level below 8.0 mg/dl considered as severe, between 8.0 to 10.9 mg/dl as moderate and mild between 11.0 to 11.9 mg/dl.

Further, the study reports a laboratory investigation was done for haemoglobin, PCV, MCV, MCH, red blood corpuscles, platelets, total WBC, neutrophils, lymphocytes and eosinophils in a randomly selected subset of 283 girls.

The researchers found that ABMN significantly lowered the clinical features of anaemia like fatigue, hair loss, headache, loss of interest and menstrual irregularities and significantly improved the level of Haemoglobin and PCV, MCV and MCH in all anaemic girls.

While talking about the impact and importance of the study findings, Dr R Meenakumari, Director at the National Institute of Siddha, also among the senior authors of the study, said, “The awareness created among adolescent girls, dietary advice and preventive care provided to them and the treatment through Siddha drugs provided therapeutic benefits to the anaemic patients. Hence Siddha drugs for anaemia can contribute to public health by providing cost-effective and accessible treatment in various settings”.